JNJ

224.16

-1.45%↓

UNH

370.76

+0.47%↑

TMO

462.35

-1.48%↓

ISRG

452.39

-1.14%↓

ABT

87.56

-2.18%↓

JNJ

224.16

-1.45%↓

UNH

370.76

+0.47%↑

TMO

462.35

-1.48%↓

ISRG

452.39

-1.14%↓

ABT

87.56

-2.18%↓

JNJ

224.16

-1.45%↓

UNH

370.76

+0.47%↑

TMO

462.35

-1.48%↓

ISRG

452.39

-1.14%↓

ABT

87.56

-2.18%↓

JNJ

224.16

-1.45%↓

UNH

370.76

+0.47%↑

TMO

462.35

-1.48%↓

ISRG

452.39

-1.14%↓

ABT

87.56

-2.18%↓

JNJ

224.16

-1.45%↓

UNH

370.76

+0.47%↑

TMO

462.35

-1.48%↓

ISRG

452.39

-1.14%↓

ABT

87.56

-2.18%↓

Home・Listă Acțiuni・Novo Nordisk A-S

Novo Nordisk A-S

Închisă

SectorSănătate

44.37 1.14

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

43.84

Maxim

44.57

Indicatori cheie
By Trading Economics
Venit	6.9B 27B
Vânzări	4.2B 79B
P/E Medie Sector	11.444 67.147
Randament dividend	4.37
Marjă de profit	33.977
Angajați	68,794
EBITDA	3.5B 37B

Recomandări
By TipRanks
Recomandări	Neutru
Prognoză pe 12 luni	-2.01% downside

Dividende
By Dow Jones
Randament dividend Medie Sector	4.37% 2.36%

Statistici piață
By TradingEconomics
Capitalizare de piață	-79B 183B
Deschiderea anterioară	43.23
Închiderea anterioară	44.37

Sentimentul știrilor

By Acuity

26%

74%

81 / 347 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Weak Bearish Evidence

62.63 / 69.23 Suport & Rezistență

Novo Nordisk A-S Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

9 mar. 2026, 10:13 UTC

Principalele dinamici ale pieței

Hims & Hers Shares Double on Report of Wegovy Tie-Up

2 mar. 2026, 10:04 UTC

Achiziții, Fuziuni, Preluări

Novo Nordisk to Invest $510 Million in Boosting Irish Manufacturing Capacity

30 apr. 2026, 13:56 UTC

Câștiguri

Eli Lilly Stock Jumps on Earnings Beat as Zepbound and Mounjaro Sales Skyrocket -- Barrons.com

23 apr. 2026, 16:47 UTC

Câștiguri

This Pharma Stock Is Soaring After Earnings. It's a Sneaky GLP-1 Play. -- Barrons.com

10 apr. 2026, 09:00 UTC

Market Talk

Novo Nordisk Sales Guidance and Wegovy Pill in Focus -- Market Talk

9 apr. 2026, 12:34 UTC

Câștiguri

Novo Nordisk: This Applies to Wegovy(R) Injection, Not the Wegovy(R) Pill

9 apr. 2026, 12:34 UTC

Câștiguri

Novo Nordisk: Delivery of Wegovy(R) Can Occur Within 48-Hours at Temperatures Up to 30degC

9 apr. 2026, 12:31 UTC

Câștiguri

Novo Nordisk: Approval Could Also Improve Supply Chain Efficiency

9 apr. 2026, 12:31 UTC

Câștiguri

Novo Nordisk: Approval Could Simplify, Lower Delivery Costs for Pharmacies, Online Partners

6 apr. 2026, 17:13 UTC

Achiziții, Fuziuni, Preluări

Soleno Stock Soars 32% on $2.9 Billion Neurocrine Buyout. Why Its Hunger Drug Is a Different Weight-Loss Play. -- Barrons.com

6 apr. 2026, 13:53 UTC

Achiziții, Fuziuni, Preluări

Soleno Stock Soars 32% on $2.9 Billion Neurocrine Buyout. Why Its Hunger Drug Is a Different Weight-Loss Play. -- Barrons.com

6 apr. 2026, 11:24 UTC

Achiziții, Fuziuni, Preluări

This Pharma Stock Is Surging 40%. Neurocrine Is Buying It in $2.9 Billion Deal. -- Barrons.com

2 apr. 2026, 08:21 UTC

Market Talk

Novo Nordisk's Obesity Pill Prescriptions Key For Shares as Eli Lilly Launches Rival -- Market Talk

1 apr. 2026, 20:07 UTC

Achiziții, Fuziuni, Preluări

Why 2026 Is Biotech's Comeback Year -- Barrons.com

30 mar. 2026, 09:59 UTC

Market Talk

Câștiguri

Novo Nordisk Earnings Could Be Solid, but Consensus Still Too High -- Market Talk

24 mar. 2026, 18:00 UTC

Achiziții, Fuziuni, Preluări

Gilead to Buy Ouro Medicines for $2.2 Billion. Why the Deal Is Key to Future Stock Gains. -- Barrons.com

24 mar. 2026, 14:25 UTC

Achiziții, Fuziuni, Preluări

Gilead to Buy Ouro Medicines for $2.2 Billion. Why the Deal Is Key to Future Stock Gains. -- Barrons.com

23 mar. 2026, 11:02 UTC

Market Talk

Câștiguri

Novo Nordisk's Weight-Loss Pill Continues to Impress -- Market Talk

17 mar. 2026, 19:01 UTC

Market Talk

Eli Lilly Outlook Seen as Too Optimistic -- Market Talk

10 mar. 2026, 11:06 UTC

Evenimente importante

Trump Soothes Market's Iran Fears. Why the -2-

10 mar. 2026, 11:06 UTC

Evenimente importante

Trump Soothes Market's Iran Fears. Why the Threat's Not Over for Stocks, Oil. -- Barrons.com

9 mar. 2026, 13:37 UTC

Market Talk

Hims, Novo Nordisk Bound by Mutual Necessity -- Market Talk

9 mar. 2026, 12:49 UTC

Market Talk

Hims Could See Near-Term Headwinds From Novo Partnership -- Market Talk

24 feb. 2026, 21:44 UTC

Câștiguri

These Stocks Are Today's Movers: AMD, Hims & Hers, Keysight, IBM, Kratos, Vir Biotechnology, Whirlpool, and More -- Barrons.com

24 feb. 2026, 19:57 UTC

Câștiguri

These Stocks Are Today's Movers: AMD, Hims & Hers, Keysight, IBM, Kratos, Vir Biotechnology, Whirlpool, and More -- Barrons.com

24 feb. 2026, 17:02 UTC

Câștiguri

These Stocks Are Today's Movers: AMD, Hims & Hers, Keysight, Novo Nordisk, IBM, Kratos, Vir Biotechnology, and More -- Barrons.com

24 feb. 2026, 15:09 UTC

Câștiguri

Hims & Hers Stock Drops. Why Earnings Are Underwhelming Investors. -- Barrons.com

24 feb. 2026, 12:44 UTC

Câștiguri

These Stocks Are Today's Movers: AMD, Home Depot, Novo Nordisk, Hims & Hers, Keysight, Vir Biotechnology, and More -- Barrons.com

24 feb. 2026, 12:06 UTC

Câștiguri

These Stocks Are Today's Movers: Home Depot, Novo Nordisk, Hims & Hers, IBM, BWX, Kratos, Vir, and More -- Barrons.com

24 feb. 2026, 11:59 UTC

Câștiguri

These Stocks Are Today's Movers: Home Depot, Novo Nordisk, Hims & Hers, IBM, BWX, Kratos, Vir, and More -- Barrons.com

Comparație

Modificare preț

Novo Nordisk A-S Așteptări

Obiectiv de preț

By TipRanks

-2.01% jos

Prognoză pe 12 luni

Medie 43 USD -2.01%

Maxim 47 USD

Minim 40 USD

În baza a 8 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruNovo Nordisk A-S - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Neutru

8 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 8 analiști care au acordat evaluări ale acțiunilor Novo Nordisk A-S - Dist în ultimele 3 luni.

Scor tehnic

By Trading Central

62.63 / 69.23Suport & Rezistență

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

81 / 347 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Novo Nordisk A-S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.